Mankind Pharma licenses Chinese insulin analogues for India launch
Mankind Pharma has signed an exclusive agreement with Chongqing Chenan Biopharmaceuticals to commercialise two basal insulin analogue products in India, subject to CDSCO approval. The company plans competitive pricing as it expands its injectable-diabetes portfolio and targets a top-three category position.
What happened
Mankind Pharma signed an exclusive China in-licensing deal to commercialise insulin degludec and an insulin degludec-aspart combination in India, subject to
Key facts
- Two basal insulin analogue products
- Ryzodeg-equivalent combination price: Rs 1,200-Rs 1,600 per 3 ml penfill/cartridge
- Diabetes therapy MAT sales: Rs 1,073 crore in July 2026
- Mankind diabetes market share: 4.4%
- Mankind Pharma shares closed at Rs 2,385, down 0.25%
Why this matters
Mankind’s China licensing deal illustrates a targeted route to broaden its diabetes portfolio quickly, using exclusive in-licensing to pursue a top-three market position.
What to watch
- CDSCO approval timing, product indications, and any requirements for bridging studies or additional clinical data.
- Launch price versus leading basal insulin analogues and the size of patient affordability discounts.
- Evidence of supply reliability, cold-chain readiness, and import dependency from Chongqing Chenan.
- Doctor adoption in major diabetes markets and formulary inclusion at hospitals, chains, insurers, and government procurement channels.
- Competitor price cuts, expanded patient-assistance programs, or new insulin analogue launches.
- Mankind commentary on diabetes-injectables revenue, margins, sales-force deployment, and ambitions for local manufacturing.
- Secure CDSCO approval and clarify the registration, import, labeling, and pharmacovigilance pathway for both insulin analogues.
- Build cold-chain, specialty-distributor, and hospital procurement capabilities ahead of launch.
- Target diabetologists, endocrinologists, high-volume general practitioners, and institutional diabetes clinics with clinical-equivalence and affordability messaging.
- Use the insulin launch to bundle or cross-promote Mankind's existing oral antidiabetic and injectable portfolio.
- Evaluate local fill-finish or technology-transfer options to reduce China sourcing concentration and improve long-term cost competitiveness.
- Prepare for price-based responses from incumbent insulin multinationals and domestic biosimilar suppliers.